MyMD Pharmaceuticals Inc (NAS:MYMD)
$ 1.9 0.09 (4.97%) Market Cap: 4.50 Mil Enterprise Value: 2.74 Mil PE Ratio: 0 PB Ratio: 0.42 GF Score: 37/100

MyMD Pharmaceuticals Inc Phase 2 Trial Update Call Transcript

Aug 02, 2023 / 08:30PM GMT
Release Date Price: $51 (+1.80%)
Operator

Good day, everyone, and welcome to the MyMD Phase 2 data call. (Operator Instructions) It is now my pleasure to turn the floor over to your host, Josh Silverman, Chairman of MyMD Pharmaceuticals. Sir, the floor is yours.

Josh Silverman
MyMD Pharmaceuticals, Inc. - Independent Chairman of the Board

Good afternoon and thank you for joining this MyMD Pharmaceuticals investor conference call to discuss our recently released Phase 2 trial results for our next-generation oral TNF-alpha inhibitor MYMD-1. My name is Josh Silverman, Chairman of MyMD Pharmaceuticals.

Before we begin, I'd like to call your attention to the Safe Harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategic beliefs, expectations, and future potential results of MyMD Pharmaceuticals, Inc.

Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, August 2, 2023, these statements are not a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot